Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB168 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Malignancies

NCT06994806 is registered in ClinicalTrials.gov with Kumquat Biosciences Inc. as lead sponsor.

NCT NCT06994806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06994806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB168 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Malignancies
Lead sponsor
Kumquat Biosciences Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 24, 2025
Completion date
May 31, 2028
Enrollment
84 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor malignancies